NOTCH1

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

Retrieved on: 
Venerdì, Marzo 8, 2024
Oncology, Health, Stem Cells, Genetics, General Health, Research, Science, Skin cancer, DMT, NPV, MD, Melanoma, Skin, TP53, Paul Khavari, AAD, NOTCH1, Abstract, Patient, Journal, Trial of the century, DNA, American Academy

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
  • “This real-world clinical study demonstrates that the DMT can help clinicians improve outcomes for cutaneous melanomas in patients of all skin types,” commented Dr. Skelsey.
  • The research found that somatic mutations in healthy-appearing sun-exposed skin indicate an increased risk for skin cancer.
  • Furthermore, these mutations capture skin cancer risk information that is not accounted for by other risk factors.

New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program

Retrieved on: 
Giovedì, Settembre 21, 2023
Immortalised cell line, PRISM, Weapon, Broad Institute, Therapy, NASH, Culture, Neoplasm, Clinical trial, Cancer, MAP3K, Research, Gene expression, MIT, Biomarker, Cell, Harvard University, TP63, Liver cancer, NOTCH1, Liver, PTPRB, ATM, HNF1A, Patient, Fatty liver disease, IDH2, Artificial intelligence, Gene, Mouse, Conditional sentence, HEPA, HCC, ALK, Pharmaceutical industry, Vaccine

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced results from a study with in which the anti-cancer activity of Hepion’s lead drug candidate, rencofilstat, was tested in a high through-put screen on 850 cancer cell lines spanning 28 types of cancer at the PRISM lab at the Broad Institute of MIT and Harvard.

Key Points: 
  • The Broad Institute is one of the few institutions in the world with such an expansive cancer cell line screening program.
  • Rencofilstat was administered at eight concentrations to each cancer cell line in culture for 5 days, followed by measurement of surviving cells to determine how effectively the drug candidate killed or suppressed proliferation of the cancer cells.
  • Defining “anti-cancer responsiveness” as 50% or greater reduction in viability following treatment, 26% of all tested cancer cell lines (220/850) spanning 86% of cancer cell types (24/28) were responsive to rencofilstat.
  • Thus, administration of rencofilstat to cancer patients with the standard regimen of once-daily oral dosing may be efficacious for those with responsive types of cancer.

Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

Retrieved on: 
Martedì, Settembre 19, 2023
Immortalised cell line, SOCS1, DNA, NASH, Hepatology, Research, Cell, Liver cancer, Gene silencing, NOTCH1, Orphan drug, PTEN, Gene expression, Apoptosis, CDKN1A, Fatty liver disease, HINT1, Artificial intelligence, Conditional sentence, HEPA, ATAC-seq, FDA, Gene, HCC, Pharmaceutical industry, Vaccine, KLF6

EDISON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced new research findings uncovering a previously unknown mechanism by which Hepion’s lead drug candidate, rencofilstat, may exert anti-cancer activity.

Key Points: 
  • Gene expression occurs from DNA sites that are in an open state, whereas genes within closed regions are silent.
  • Hepion’s ATAC-Seq experiments on two liver cancer cell lines revealed that rencofilstat significantly changed the open-closed state of DNA.
  • Thus, changes in gene accessibility produced by rencofilstat favored an anti-cancer mode of action.
  • Hepion has also received FDA clearance to begin a Phase 2 clinical trial of rencofilstat in HCC, which remains the most common type of liver cancer, accounting for up to 90% of all primary liver cancers.

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Retrieved on: 
Giovedì, Aprile 13, 2023
CLL, NRAS, KRAS, MYC, AACR, Molecule, TP53, Chronic lymphocytic leukemia, Menin, ITD, Acute leukemia, American Association for Cancer Research, MEK, Doctor of Philosophy, BTK, Gene expression profiling, MEN1, NOTCH1, AML, BCL2, Patient, DSM-IV codes, Proteasome inhibitor, Cancer, Acute myeloid leukemia, Growth, Leukemia, Therapy, Gene, Disease, Pharmaceutical industry, Vaccine, Biology, FLT3

Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.

Key Points: 
  • Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.
  • Menin is an epigenetic protein that drives oncogenic function through transcriptional regulation directed by its interactions with various protein partners.
  • Additionally, we show benefit of combinatorial approaches of menin and FLT3 covalent inhibitors with MEK and BCL2 blockade.
  • These data provide initial pre-clinical evidence for combining pathway specific inhibitors as a promising therapeutic strategy for further investigation in acute leukemia.

Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial

Retrieved on: 
Giovedì, Ottobre 27, 2022
Survival, Diabetes, U.S. Securities and Exchange Commission, SEC, Securities Exchange Act of 1934, NPM1, MM, Safety, Cancer, Chronic leukemia, DLBCL, TP53, Risk, CLL, NOTCH1, Patient, Osteopathic medicine in Canada, Board, Multiple myeloma, ALL, ASCO, Research, Rai, GLOBE, B-cell lymphoma, Securities Act of 1933, Lists of diseases, Drug Quality and Security Act, Institutional review board, Chromosome, Vaccine, Pharmaceutical industry

Additional information about the Phase I clinical trial of BMF-219 can be found at ClinicalTrials.gov using the identifier NCT05153330.

Key Points: 
  • Additional information about the Phase I clinical trial of BMF-219 can be found at ClinicalTrials.gov using the identifier NCT05153330.
  • CLL is a chronic leukemia that progresses relatively slowly and typically impacts older adults.
  • Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Retrieved on: 
Giovedì, Giugno 9, 2022
Institute, Platform, Chronic lymphocytic leukemia, Sophia, Technology, Research, Generalitat, U.S. Securities and Exchange Commission, Blood, SF3B1, Forward-looking statement, Partnership, Solution, Trisomy, Faculty, Acute myeloid leukemia, Lymphoma, BTK, CLL, Biomedical Research, Noise, DDM, CNV, Guideline, Algorithm, SNV calling from NGS data, University, Health, Patient, DNA, PLCG2, Sophia Genetics, University of Barcelona, Software as a service, Leukemia, NGS, GENETICS, LinkedIn, Disease, Environment, Catalan, ATM, TP53, NOTCH1, Workflow, BCL2, 2015–16 Catalan government formation, Twitter, Instagram, Medical device, Pharmaceutical industry, Genetics, Hematology, Medicine

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.

Key Points: 
  • SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.
  • The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis.
  • "We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world.
  • Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to its management.

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Retrieved on: 
Giovedì, Giugno 9, 2022
Institute, Platform, Chronic lymphocytic leukemia, Sophia, Technology, Research, Generalitat, U.S. Securities and Exchange Commission, Blood, SF3B1, Forward-looking statement, Partnership, Solution, Trisomy, Faculty, Acute myeloid leukemia, Lymphoma, BTK, CLL, Biomedical Research, Noise, DDM, CNV, Guideline, Algorithm, SNV calling from NGS data, University, Health, Patient, DNA, PLCG2, Sophia Genetics, University of Barcelona, Software as a service, Leukemia, NGS, GENETICS, LinkedIn, Disease, Environment, Catalan, ATM, TP53, NOTCH1, Workflow, BCL2, 2015–16 Catalan government formation, Twitter, Instagram, Medical device, Pharmaceutical industry, Genetics, Hematology, Medicine

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.

Key Points: 
  • SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.
  • The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis.
  • "We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world.
  • Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to its management.

Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022

Retrieved on: 
Giovedì, Maggio 26, 2022
Cancer, Chromosome, Disease, Nasdaq, Chronic lymphocytic leukemia, Abstract, Leadership, IC50, Patient, BCL2, Menin, Gene expression, Rai, Lists of diseases, American Society of Clinical Oncology, Society, DLBCL, Board, Swansea Bay University Health Board, MLL, CLL, ASCO, TIP, Collection, GLOBE, Haematopoiesis, NOTCH1, TP53, Medical imaging, Pharmaceutical industry, Vaccine

Once released at the ASCO Annual Meeting, the preclinical and TIP presentations can be viewed on Biomeas website at https://biomeafusion.com/publications .

Key Points: 
  • Once released at the ASCO Annual Meeting, the preclinical and TIP presentations can be viewed on Biomeas website at https://biomeafusion.com/publications .
  • BMF-219 demonstrated potency across ex vivo CLL tumor models with varying cytogenetic risk profiles and Rai stages, indicating broad activity with over 98% cell lethality in all of these models.
  • Additionally, BMF-219 showed consistently strong activity compared to venetoclax (used as a positive control) and significantly greater activity than a clinical non-covalent (reversible) menin inhibitor.
  • Preclinical activity of irreversible Menin inhibitor, BMF-219, in chronic lymphocytic leukemia.

Study Confirms Nutrient's Role in Childhood Blood Cancer

Retrieved on: 
Mercoledì, Dicembre 22, 2021
DNA, Laura, Organic acid, NYU Langone Health, Publishing, Doctor of Philosophy, National Institutes of Health, Patient, Lists of diseases, Cancer, Meat, Machine learning, Mouse, Bone marrow, Cell, Nature, National, Valine, New York State Department of Health, Venetoclax, Diet, NYU, Elias C. Aifantis, Protein, Leukemia, American Association, American Cancer Society, Gene, Association, Muscle, New York University Grossman School of Medicine, Department, Intelligentsia, Acute lymphoblastic leukemia, Alvin J. Siteman Cancer Center, Brain damage, Nucleotide, Research, NOTCH1, Hermann, Clinical trial, Lysine, Dietary supplement, Vaccine, Pharmaceutical industry, Pathology

The diet also reduced circulating blood cancer cells by at least half and in some cases to undetectable levels.

Key Points: 
  • The diet also reduced circulating blood cancer cells by at least half and in some cases to undetectable levels.
  • He cautions that dietary strategies alone for treating cancer have been tried for decades with little scientific evidence of any benefit.
  • The American Cancer Society estimates that more than 1,500 Americans, mostly children, die each year from T cell acute lymphoblastic leukemia.
  • Study co-investigator Aristotelis Tsirigos, PhD, serves as a scientific advisor to Intelligencia.AI in New York City, a software company that applies machine learning to cancer drug development.